Welcome to an environment of encompassing Alpha-1 support, brought to you by ARALAST augmentation therapy. Our purpose? To provide you with continuous support that's easy to access online or over the phone.

Want to talk to an ARALAST AATmosphere Representative, Specialized Nurse, Alpha-1 Advocate (person with Alpha-1), or Insurance Specialist?

Just call 1-866-ARALAST toll-free, Monday through Friday, 8am to 5pm CT.

ARALAST [Alpha₁-Proteinase Inhibitor (Human)] is indicated for chronic augmentation therapy in patients having congenital deficiency of A₁-PI with clinically evident emphysema. ARALAST is not indicated as therapy for lung disease patients in whom congenital A₁-PI deficiency has not been established.

Important Safety Information

• ARALAST is contraindicated in individuals with selective IgA deficiencies (IgA level less than 15mg/dL) who have known antibody against IgA, since they may experience severe reactions, including a severe, potentially life-threatening allergic reaction to IgA, which may be present.
• The most common symptoms during the clinical study were headache (0.3%) and sleepiness (0.3%). Post-market adverse event data have indicated reports of infusion site pain associated with the administration of ARALAST.
• Pregnancy Category C, reproduction studies have not been conducted with ARALAST.
• As with all plasma-derived therapeutics, the potential to transmit infectious agents cannot be totally eliminated.

Please see the ARALAST Full Prescribing Information.

Copyright ©2008. Baxter Healthcare Corporation. All rights reserved.